We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock

Delisted

KDNY was delisted on the 10th of August, 2023.

103 hedge funds and large institutions have $707M invested in Chinook Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding in top 10

Funds holding in top 10: 14 (+3)

257% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 7

194% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 17

96% more capital invested

Capital invested by funds: $362M → $707M (+$345M)

21% more funds holding

Funds holding: 85103 (+18)

2% more call options, than puts

Call options by funds: $47K | Put options by funds: $46K

Holders
103
Holders Change
+18
Holders Change %
+21.18%
% of All Funds
1.59%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.06%
New
25
Increased
50
Reduced
17
Closed
7
Calls
$47K
Puts
$46K
Net Calls
+$1K
Net Calls Change
-$153K

KDNY Hedge Fund Activity: Q4 2021 in Review

103 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2021, worth a combined $707M — up 96% from $362M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KDNY positions and 7 closed out — a net gain of 18 holders — while 50 added to existing stakes and 17 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $25.6M. The largest seller was Millennium Management, cutting an estimated $4.47M.

  • 103 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2021, up from 85 in Q3 2021.
  • Funds reported $707M of Chinook Therapeutics, Inc. Common Stock stock for Q4 2021, up 96% quarter-over-quarter.
  • 25 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2021 and 7 closed out, a net change of +18 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2021 was BVF Inc, an estimated $25.6M added.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $4.47M sold.

Based on aggregated 13F filings for Q4 2021.